Epigenetic regulation of immune checkpoints: another target for cancer immunotherapy?

被引:35
作者
Ali, Mahmoud A. [1 ]
Matboli, Marwa [2 ]
Tarek, Marwa [2 ]
Reda, Maged [3 ]
Kamal, M. Kamal [3 ]
Nouh, Mahmoud [3 ]
Ashry, Ahmed M. [3 ]
El-Bab, Ahmed Fath [3 ]
Mesalam, Hend A. [4 ]
Shafei, Ayman El-Sayed [5 ]
Abdel-Rahman, Omar [6 ]
机构
[1] Armed Forces Coll Med, Microbiol & Immunol, Cairo, Egypt
[2] Ain Shams Univ, Fac Med, Med Biochem & Mol Biol Dept, Oncol Diagnost Unit, Cairo, Egypt
[3] Armed Forces Coll Med, Cairo, Egypt
[4] Al Azhar Univ, Fac Med, Cairo, Egypt
[5] Armed Forces Coll Med, Phys Med, Cairo, Egypt
[6] Ain Shams Univ, Dept Clin Oncol, Fac Med, Cairo, Egypt
关键词
acetylation; cancer; epigenetics; immune checkpoint; lncRNA; methylation; miRNA; DNA METHYLATION; HISTONE ACETYLATION; LUNG-CANCER; EXPRESSION; INHIBITORS; CELLS; PD-1; PATHWAY; RISK; DIFFERENTIATION;
D O I
10.2217/imt-2016-0111
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
071005 [微生物学]; 100108 [医学免疫学];
摘要
Epigenetic changes in oncogenes and tumor-suppressor genes contribute to carcinogenesis. Understanding the epigenetic and genetic components of tumor immune evasion is crucial. Few cancer genetic mutations have been linked to direct correlations with immune evasion. Studies on the epigenetic modulation of the immune checkpoints have revealed a critical interaction between epigenetic and immune modulation. Epigenetic modifiers can activate many silenced genes. Some of them are immune checkpoints regulators that turn on immune responses and others turn them off resulting in immune evasion. Many forms of epigenetic inheritance mechanisms may play a role in regulation of immune checkpoints including: covalent modifications, noncoding RNA and histone modifications. In this review, we will show how the potential interaction between epigenetic and immune modulation may lead to new approaches for specific epigenome/immunome-targeted therapies for cancer.
引用
收藏
页码:99 / 108
页数:10
相关论文
共 79 条
[1]
Treatment-associated Fatigue in Cancer Patients Treated with Immune Checkpoint Inhibitors; a Systematic Review and Meta-analysis [J].
Abdel-Rahman, O. ;
Helbling, D. ;
Schmidt, J. ;
Petrausch, U. ;
Giryes, A. ;
Mehrabi, A. ;
Schob, O. ;
Mannhart, M. ;
Zidan, A. ;
Oweira, H. .
CLINICAL ONCOLOGY, 2016, 28 (10) :E127-E138
[3]
Risk of pneumonitis in cancer patients treated with immune checkpoint inhibitors: a meta-analysis [J].
Abdel-Rahman, Omar ;
Fouad, Mona .
THERAPEUTIC ADVANCES IN RESPIRATORY DISEASE, 2016, 10 (03) :183-193
[4]
A network meta-analysis of the risk of immune-related renal toxicity in cancer patients treated with immune checkpoint inhibitors [J].
Abdel-Rahman, Omar ;
Fouad, Mona .
IMMUNOTHERAPY, 2016, 8 (05) :665-674
[5]
Risk of gastrointestinal complications in cancer patients treated with immune checkpoint inhibitors: a meta-analysis [J].
Abdel-Rahman, Omar ;
ElHalawani, Hesham ;
Fouad, Mona .
IMMUNOTHERAPY, 2015, 7 (11) :1213-1227
[6]
Risk of elevated transaminases in cancer patients treated with immune checkpoint inhibitors: a meta-analysis [J].
Abdel-Rahman, Omar ;
ElHalawani, Hesham ;
Fouad, Mona .
EXPERT OPINION ON DRUG SAFETY, 2015, 14 (10) :1507-1518
[7]
Risk of cutaneous toxicities in patients with solid tumors treated with immune checkpoint inhibitors: a meta-analysis [J].
Abdel-Rahman, Omar ;
ElHalawani, Hesham ;
Fouad, Mona .
FUTURE ONCOLOGY, 2015, 11 (17) :2471-2484
[8]
Targeting FGF receptors in colorectal cancer: from bench side to bed side [J].
Abdel-Rahman, Omar .
FUTURE ONCOLOGY, 2015, 11 (09) :1373-1379
[9]
Allis C.D., 2015, Epigenetics.
[10]
Selective recognition of methylated lysine 9 on histone H3 by the HP1 chromo domain [J].
Bannister, AJ ;
Zegerman, P ;
Partridge, JF ;
Miska, EA ;
Thomas, JO ;
Allshire, RC ;
Kouzarides, T .
NATURE, 2001, 410 (6824) :120-124